First Republic Investment Management Inc. Purchases 12,609 Shares of Sanofi SA (SNY)
First Republic Investment Management Inc. lifted its position in shares of Sanofi SA (NYSE:SNY) by 12.3% during the second quarter, HoldingsChannel reports. The institutional investor owned 115,412 shares of the company’s stock after acquiring an additional 12,609 shares during the quarter. First Republic Investment Management Inc.’s holdings in Sanofi were worth $4,618,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Private Capital Group LLC grew its position in shares of Sanofi by 271.3% during the 1st quarter. Private Capital Group LLC now owns 2,577 shares of the company’s stock worth $103,000 after buying an additional 1,883 shares in the last quarter. IHT Wealth Management LLC boosted its position in Sanofi by 246.6% during the first quarter. IHT Wealth Management LLC now owns 4,239 shares of the company’s stock valued at $167,000 after purchasing an additional 3,016 shares in the last quarter. Squar Milner Financial Services LLC bought a new stake in Sanofi during the second quarter valued at about $169,000. GWM Advisors LLC bought a new stake in Sanofi during the first quarter valued at about $201,000. Finally, SVA Plumb Wealth Management LLC bought a new stake in Sanofi during the first quarter valued at about $218,000. 7.54% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE SNY opened at $44.39 on Friday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. The stock has a market capitalization of $106.52 billion, a price-to-earnings ratio of 14.18, a price-to-earnings-growth ratio of 2.28 and a beta of 0.85. Sanofi SA has a fifty-two week low of $37.43 and a fifty-two week high of $50.65.
SNY has been the topic of a number of recent research reports. Citigroup raised Sanofi from a “neutral” rating to a “buy” rating in a research report on Friday, August 10th. ValuEngine downgraded Sanofi from a “sell” rating to a “strong sell” rating in a research report on Saturday, June 2nd. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Tuesday, July 31st. Zacks Investment Research raised Sanofi from a “sell” rating to a “hold” rating in a research report on Wednesday, June 13th. Finally, Argus raised their price objective on Sanofi from $46.00 to $48.00 and gave the company a “buy” rating in a research report on Friday, August 24th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company’s stock. Sanofi has an average rating of “Hold” and a consensus price target of $49.00.
In other Sanofi news, major shareholder Sanofi sold 104,552 shares of the firm’s stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $406.68, for a total value of $42,519,207.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.00% of the stock is currently owned by company insiders.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Recommended Story: What is Compound Annual Growth Rate (CAGR)?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.